Alcobra Ltd. (NASDAQ:ADHD) traded up 5.9% on Monday . The stock traded as high as $4.32 and last traded at $4.30, with a volume of 61,932 shares traded. The stock had previously closed at $4.06.

Several equities research analysts have weighed in on the company. Zacks Investment Research downgraded Alcobra from a “buy” rating to a “hold” rating in a research report on Wednesday, April 27th. Roth Capital reissued a “buy” rating and set a $12.00 target price on shares of Alcobra in a research note on Tuesday, June 21st. Canaccord Genuity assumed coverage on shares of Alcobra in a research note on Tuesday, June 7th. They set a “buy” rating on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of Alcobra in a research note on Tuesday, June 7th. They set a “buy” rating and a $16.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $10.63.

The firm’s 50-day moving average price is $4.71 and its 200 day moving average price is $4.69. The company’s market cap is $116.86 million.

Alcobra (NASDAQ:ADHD) last announced its quarterly earnings results on Monday, May 16th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. On average, equities research analysts anticipate that Alcobra Ltd. will post ($0.98) earnings per share for the current fiscal year.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.